
    
      This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated
      interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19
      and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in
      mild to moderate symptomatic patients who consent to randomization following a new diagnosis
      in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants
      daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test
      remained positive..
    
  